Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, K. Bhalla, O. Ottmann, F. Giles, M. Albitar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Most studies test for mutations in the kinase domain of the abl gene in chronic myeloid leukemia (CML) using peripheral blood (PB) cells. Frequently, progression of the disease manifests with increased blasts in bone marrow (BM) and not in PB. Simultaneous analysis of plasma, PB cells and BM cells from 41 imatinib-resistent CML patients showed mutations in 63% of PB cells and 68% of plasma or BM cells (P=0.04). In discordant patients, 13 mutations were detected in plasma, 11 in BM cells and 9 in PB cells. The T315I mutation was detected in plasma and BM but not PB cells in one patient. We detected no mutations in the plasma of 45 previously untreated CML patients, but two of these patients showed mutations in plasma and not cells by 9 months on therapy. Circulating plasma mRNA is a reliable alternative to BM mRNA for detecting ABL mutations.

Original languageEnglish (US)
Pages (from-to)1989-1991
Number of pages3
JournalLeukemia
Volume20
Issue number11
DOIs
StatePublished - Nov 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA'. Together they form a unique fingerprint.

Cite this